MabThera rituximab regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending the use of MabThera rituximab from Roche as a first-line maintenance treatment of advanced follicular non-Hodgkin's lymphoma (NHL) in patients who have responded to first-line induction therapy with MabThera in combination with chemotherapy. ...